2/4
08:30 am
srpt
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
Medium
Report
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
2/1
07:03 pm
srpt
Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]
Low
Report
Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]
2/1
02:53 am
srpt
Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? [Yahoo! Finance]
Low
Report
Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? [Yahoo! Finance]
1/31
12:28 am
srpt
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags [Yahoo! Finance]
Low
Report
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags [Yahoo! Finance]
1/28
08:03 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $20.00 price target on the stock.
Medium
Report
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $20.00 price target on the stock.
1/27
08:04 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
1/27
07:07 am
srpt
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
1/26
10:52 pm
srpt
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Short-Term Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Short-Term Share Price Momentum [Yahoo! Finance]
1/26
08:18 am
srpt
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients [Yahoo! Finance]
Low
Report
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients [Yahoo! Finance]
1/26
08:00 am
srpt
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
Low
Report
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
1/23
04:05 pm
srpt
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
Medium
Report
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
1/23
09:03 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Wedbush from $32.00 to $34.00. They now have an "outperform" rating on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Wedbush from $32.00 to $34.00. They now have an "outperform" rating on the stock.
1/21
10:57 pm
srpt
2 Beaten-Down Stocks That Could Sink Even More in 2026 [Yahoo! Finance]
Low
Report
2 Beaten-Down Stocks That Could Sink Even More in 2026 [Yahoo! Finance]
1/17
06:31 am
srpt
Has Sarepta Therapeutics (SRPT) Fallen Too Far After 82% One-Year Share Price Drop? [Yahoo! Finance]
Low
Report
Has Sarepta Therapeutics (SRPT) Fallen Too Far After 82% One-Year Share Price Drop? [Yahoo! Finance]
1/16
11:51 am
srpt
Sarepta Preliminary Results: Not What The Market Wanted To Hear [Seeking Alpha]
Neutral
Report
Sarepta Preliminary Results: Not What The Market Wanted To Hear [Seeking Alpha]
1/16
09:32 am
srpt
Sarepta Therapeutics: Is Elevidys A Bust? [Seeking Alpha]
Low
Report
Sarepta Therapeutics: Is Elevidys A Bust? [Seeking Alpha]
1/15
05:20 pm
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Royal Bank Of Canada from $16.00 to $18.00. They now have a "sector perform" rating on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Royal Bank Of Canada from $16.00 to $18.00. They now have a "sector perform" rating on the stock.
1/14
08:04 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
1/12
12:05 pm
srpt
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues [Yahoo! Finance]
Low
Report
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues [Yahoo! Finance]
1/12
11:58 am
srpt
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Low
Report
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
1/8
12:22 am
srpt
Assessing Sarepta Therapeutics (SRPT) Valuation After SRP-1005 Huntington's Disease Trial Application [Yahoo! Finance]
Low
Report
Assessing Sarepta Therapeutics (SRPT) Valuation After SRP-1005 Huntington's Disease Trial Application [Yahoo! Finance]
1/7
09:17 am
srpt
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease [Yahoo! Finance]
1/7
08:30 am
srpt
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
Medium
Report
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
1/5
08:30 am
srpt
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/31
05:20 pm
srpt
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)